Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. Basic financial performance shows increased net loss and stock compensation, but cash reserves have grown. Product development updates are promising, with multiple trials underway. Market strategy lacks clarity due to abstract rejection and unclear trial plans. Financial health is stable, with increased cash reserves. Shareholder return plans are not mentioned. Q&A reveals potential trial delays and management's lack of clarity on certain issues, balancing positive trial progress. Overall, the sentiment is neutral due to balanced positives and negatives, and the lack of market cap information limits the prediction's precision.
Key Financial Performance
Research and Development (R&D) Expenses (Q4 2025) $9.9 million, a 65% increase year-over-year from $6 million in Q4 2024. The increase was primarily due to higher clinical trial and manufacturing costs for soquelitinib development and increased personnel costs.
Research and Development (R&D) Expenses (Full Year 2025) $33.7 million, a 73.7% increase year-over-year from $19.4 million in 2024. The increase was primarily due to higher clinical trial and manufacturing costs for soquelitinib development and increased personnel costs.
Net Loss (Q4 2025) $12.3 million, a slight increase from $12.1 million in Q4 2024. The increase was due to noncash losses of $0.7 million from equity method investment in Angel Pharmaceuticals, compared to $2.2 million in Q4 2024, and a noncash loss of $2.3 million in Q4 2024 related to warrant liability.
Stock Compensation Expense (Q4 2025) $1.6 million, a 100% increase year-over-year from $0.8 million in Q4 2024.
Cash, Cash Equivalents, and Marketable Securities (End of 2025) $56.8 million, a 9.2% increase year-over-year from $52 million at the end of 2024. The increase was due to an upsized underwritten public offering in January 2025, generating net proceeds of $189 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Soquelitinib development: Significant progress in advancing soquelitinib, a first-in-class selective ITK inhibitor, with promising results in Phase I/Ib trials for peripheral T-cell lymphoma and atopic dermatitis. Phase III PTCL trial and Phase II atopic dermatitis trial are ongoing, with plans to expand into mid-stage trials for other inflammatory diseases like hidradenitis suppurativa and asthma.
Efficacy of Soquelitinib: Cohort 4 of the Phase I atopic dermatitis trial showed a 72% mean reduction in EASI scores compared to 40% for placebo. 75% of patients achieved EASI 75, and the drug demonstrated durable responses with no disease rebound.
Safety of Soquelitinib: No new safety signals observed. Adverse events were similar between placebo and active groups, with no significant lab abnormalities or serious infections reported.
Market positioning of Soquelitinib: Soquelitinib is positioned as a potential leading therapy for atopic dermatitis and other inflammatory diseases due to its novel mechanism of action, safety, and efficacy. It is expected to compete strongly with existing therapies like Dupixent and Rinvoq.
Financial position: Corvus Pharmaceuticals closed a $200 million financing, extending its cash runway into Q2 2028. Cash and equivalents totaled $246 million as of December 31, 2025.
Clinical trial expansion: Plans to initiate Phase II trials for hidradenitis suppurativa and asthma in 2026, alongside ongoing trials for atopic dermatitis and PTCL.
Pipeline expansion: Corvus is leveraging soquelitinib's ITK inhibition mechanism to explore treatments for a broader range of inflammatory and autoimmune diseases, including hidradenitis suppurativa and asthma.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Increased R&D Expenses: Research and development expenses increased significantly in 2025 compared to 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib and increased personnel costs. This could strain financial resources if not managed effectively.
Net Loss: The company reported a net loss of $12.3 million for Q4 2025, slightly higher than the $12.1 million loss in Q4 2024. Persistent losses could impact financial sustainability.
Regulatory Risks: The company’s forward-looking statements are subject to risks and uncertainties, including regulatory hurdles that could delay or prevent product approvals.
Clinical Trial Risks: Ongoing clinical trials for soquelitinib in various indications, including atopic dermatitis and PTCL, carry inherent risks such as failure to meet efficacy or safety endpoints, which could impact future development and commercialization.
Market Competition: Soquelitinib faces competition from existing therapies like Dupixent and Rinvoq, as well as other emerging treatments, which could limit its market share.
Supply Chain and Manufacturing Risks: Higher manufacturing costs and potential supply chain disruptions could affect the timely production and distribution of soquelitinib.
Economic Uncertainties: Broader economic conditions could impact funding availability and investor confidence, potentially affecting the company’s cash runway and operational plans.
Safety Concerns: Although no new safety signals were observed, questions about potential EBV viral reactivation and other long-term safety concerns could arise, impacting patient and investor confidence.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cash runway: The company has extended its cash runway into the second quarter of 2028, supported by a recent $200 million financing.
Phase III PTCL trial: Ongoing enrollment with an interim analysis expected later this year.
Phase II atopic dermatitis trial: Recently initiated, planned to enroll 200 patients with moderate to severe disease. Data from this trial is anticipated in mid-2027.
Pipeline expansion: Plans to initiate Phase II trials for hidradenitis suppurativa and asthma later this year.
Angel Pharmaceuticals collaboration: Angel Pharmaceuticals is conducting a Phase Ib/II trial in atopic dermatitis in China, with results from initial cohorts expected late this year.
Upcoming data presentations: The company plans to present Phase I clinical data and biomarker results at the Society for Investigative Dermatology Annual Meeting in mid-May.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the anticipated timeline for data readouts from Angel Pharmaceuticals' trials and the PTCL trial?
A:Angel Pharmaceuticals will have initial data from their placebo randomized trial later this year, focusing on 100 mg BID and 200 mg QD doses. The next part of the study, involving 200 mg BID and 400 mg QD, will likely be completed by mid-2027. The PTCL trial will have an interim review later this year, with complete results expected in late 2027.
Q:What data will be presented at the SID meeting in May?
A:The SID meeting will feature updates on durability, new biomarker discoveries, and clinical data. The focus will be on T regulatory cells, JAK-STAT signaling, and the impact on multiple cytokine pathways like IL-5, IL-4, and IL-17.
Q:What is the benchmark for the Phase II trial in HS, and how does it compare to approved agents like IL-17?
A:The benchmark is the corrected HiSCR scores, which are around 25%. The company expects efficacy as good or better than existing biologics, but the optimum dose still needs to be determined.
Q:Why was the company's abstract not accepted for the AAD meeting, and what are their thoughts on this?
A:The company believes the abstract rejection process is capricious and influenced by various factors, including the organization's familiarity with the company. They are not overly concerned and consider the SID meeting to be more scientifically rigorous.
Q:Will there be updates on the Phase II trial in AD before its completion in mid-2027?
A:No, the Phase II trial in AD is placebo-controlled, randomized, and blinded. Data will not be available until the trial is completed. However, updates may come from the Angel trial, which is also blinded but allows data review after each cohort.
Q:How does the company view the lack of good preclinical models for HS?
A:The company acknowledges the lack of good animal models for HS but emphasizes the importance of IL-17 in human studies. They believe their drug, which blocks IL-17 and other cytokines, has an advantage in treating HS.
Q:What is the company's strategy for dosing in asthma trials?
A:The dosing strategy for asthma trials will be informed by the AD and PTCL studies. The same dosing regimens are expected to be used, and the company has a biomarker to measure drug efficacy.
Q:What is the significance of the ALPS trial, and how might it impact other indications?
A:The ALPS trial demonstrates the drug's activity and safety in autoimmune diseases. While it may not directly predict efficacy in other diseases like lupus, it serves as a human model for aberrant auto-inflammatory responses.
Q:What types of PTCL are being enrolled in the Phase III trial, and how is the trial progressing?
A:The trial is enrolling PTCL NOS, anaplastic lymphomas (ALK positive), and T follicular helper types. It is progressing as planned, with patients randomized to soquelitinib or investigator's choice of belinostat or pralatrexate.
Q:What are the company's thoughts on combining asthma and AD indications in a single trial?
A:The company finds it challenging to combine asthma and AD indications in a single trial due to statistical and logistical complexities. Separate trials are required for each indication.
Q:How is the company addressing the durability of response in their trials?
A:The Phase II trial includes a 90-day blinded follow-up to assess durability, although it is not a primary endpoint. The company is exploring the broader implications of durability across autoimmune diseases.
Q:Will the upcoming asthma study focus on eosinophilic asthma or include a broader population?
A:The company is leaning towards including a broader population rather than focusing solely on eosinophilic asthma. The protocol is still under discussion.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing why their abstract was not accepted for the AAD meeting, attributing it to a capricious process without providing specific reasons. They also did not provide a clear explanation for how they would handle the statistical and logistical challenges of combining asthma and AD indications in a single trial.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Corvus Pharmaceuticals
Corvus equity
Financial Results
Form Real
Full Update
Leiv overview
Mr Real
Officer Chief
Pharmaceuticals Full
Pharmaceuticals noncash
RD increase
RD trial
Results Conference
Sciences filing
Update Financial
afternoon Corvus
equity method
expense month
financing forma
forma cash
group investor
increase RD
investment Angel
investor proceeds
law Leiv
liability stock
loss Corvus
method investment
month period
noncash loss
offering premier
period RD
period loss
CRVS Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call summary presents a mixed picture. Basic financial performance shows increased net loss and stock compensation, but cash reserves have grown. Product development updates are promising, with multiple trials underway. Market strategy lacks clarity due to abstract rejection and unclear trial plans. Financial health is stable, with increased cash reserves. Shareholder return plans are not mentioned. Q&A reveals potential trial delays and management's lack of clarity on certain issues, balancing positive trial progress. Overall, the sentiment is neutral due to balanced positives and negatives, and the lack of market cap information limits the prediction's precision.
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed outlook. The company's financial performance and product development show promise with ongoing trials and potential applications in multiple indications. However, there are uncertainties regarding trial outcomes and management's reluctance to provide clear guidance on certain metrics. The Q&A section reveals some positive analyst sentiment but also highlights risks and unclear management responses. The lack of guidance and need for additional funding are concerns. Overall, the stock price reaction is expected to be neutral in the short term, as the positive aspects are balanced by uncertainties and financial challenges.
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed outlook. Financial performance shows increased R&D expenses and a net loss, but cash reserves are sufficient until late 2026. Product development is progressing, with Phase II trials on track and partnerships supporting expansion. However, the reliance on soquelitinib and competitive pressures pose risks. The Q&A highlights strategic focus but lacks clarity on some future plans. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement in either direction.
CRVS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
